Sales of Biogen’s costly new Alzheimer’s drug fall far short of expectations. October 20, 2021 Auto Bot Aduhelm (Drug), alzheimer's disease, Biogen Inc, Cleveland Clinic, Food and Drug Administration, Medicare, Vounatsos, Michel 0 The drug, Aduhelm, brought in $300,000 in revenue in its first full three months of availability. The company expects the drug to generate minimal revenue for the rest of the year.